Table 1.
Randomized: n = 382 Male (M) n = 105 (27.5%); Female (F) n = 277 (72.5%) |
||||
---|---|---|---|---|
Cumulative dose analysis: patients on treatment |
Cumulative time analysis: patients on treatment |
|||
MIN quartile (n) | MAX quartile (n) | MIN quartile (n) | MAX quartile (n) | |
Day 1 | 96 M 20.8%; F 79.2% | 95 M 32.6%; F 67.4% | 96 M 19.8%; F 80.2% | 95 M 34.7%; F 65.3% |
Year 2 | 80 (83.3%) | 94 (98.9%) | 78 (81.3%) | 93 (97.9%) |
Year 4 | 49 (51.0%) | 94 (98.9%) | 45 (46.9%) | 93 (97.9%) |
Year 6 | 23 (24.0%) | 69 (72.6%) | 12 (12.5%) | 72 (75.8%) |
LTFU | 15 (15.6%) M 33.3%; F 67.7% | 63 (66.3%) M 34.9%; F 65.1% | 4 (4.2%) M 25.0%; F 75.0% | 71 (74.7%) M 33.8%; F 66.2% |
F, female; LTFU, long-term follow up; M, male; MAX, maximum (highest quartile); MIN, minimum (lowest quartile).